Search - tctmd.com

Displaying 21 - 40 of 260

Sort: Relevancy | Date

Presentation TCT 2022

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

Presenter: Matthias Lutz

September 17, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

Presentation TCT 2021

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

November 04, 2021

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

L.A. McKeown

October 25, 2021

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case

Yael L. Maxwell

March 03, 2021

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

Todd Neale

October 14, 2020

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Todd Neale

March 31, 2020

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

News Daily News

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

L.A. McKeown

March 09, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

Advertisement

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

Good Long-term Results With FANTOM BVS, but More Data Needed

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content